Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Oncology > Online
COMMENTARY   Open Access     Cite

Clinical breakthroughs of B7-H3-targeted antibody-drug conjugates in solid tumors

  • 1.

    First Clinical College, Guangzhou Medical University, Guangzhou 511436, China

  • 2.

    State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

More Information
  • Author Bio: Rongzhen Huang and; Lunlang Zhou wrote the papaer
  • Corresponding author: 2021390052@gzhmu.edu.cn
  • Received Date:  April 07, 2026
    Accepted Date:  September 22, 2026
    Published Online:  September 24, 2026
The Innovation Oncology  https://doi.org/10.59717/j.xinn-oncol.2026.100034  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Ma Y., Yang Y., Huang Y., et al. (2025). A B7H3-targeting antibody–drug conjugate in advanced solid tumors: A phase 1/1b trial. Nat. Med. 31:1949−1957. DOI:10.1038/s41591-025-03600-2

    View in Article CrossRef Google Scholar

    [2] Duan J., Sun Y., Wang Q., et al. (2026). HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial. Cancer Cell 44:846−857. DOI:10.1016/j.ccell.2026.02.006

    View in Article CrossRef Google Scholar

    [3] Rudin C.M., Johnson M.L., Paz-Ares L., et al. (2026). Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial. J. Clin. Oncol. 44:261−273. DOI:10.1200/JCO-25-02142

    View in Article CrossRef Google Scholar

    [4] Qiu Y., Gu T., Wang T., et al. (2026). Integrated radio-theranostics using a [89Zr]Zr-/[177Lu]Lu-labeled B7-H3 antibody-drug conjugate for prostate cancer. Theranostics 16:6132−6144. DOI:10.7150/thno.125878

    View in Article CrossRef Google Scholar

    [5] Zhao Y., Liu H., Meng X., et al. (2026). Tambotatug pelitecan in small-cell lung cancer after platinum-based therapy. N. Engl. J. Med. Published online September 12:2026. DOI:10.1056/NEJMoa2610229

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Huang R., Zhou L. and Chen H. (2026). Clinical breakthroughs of B7-H3-targeted antibody-drug conjugates in solid tumors. The Innovation Oncology 1:100034. https://doi.org/10.59717/j.xinn-oncol.2026.100034
    Huang R., Zhou L. and Chen H. (2026). Clinical breakthroughs of B7-H3-targeted antibody-drug conjugates in solid tumors. The Innovation Oncology 1:100034. https://doi.org/10.59717/j.xinn-oncol.2026.100034

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(120) PDF downloads(118)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Published articles are licensed under CC BY with copyright retained by the authors.
    All contents on this site: Copyright © 2026 INNOVATION PRESS. All rights are reserved.